HC Wainwright Cuts Curis (NASDAQ:CRIS) Price Target to $16.00

Curis (NASDAQ:CRIS) had its price objective lowered by HC Wainwright from $20.00 to $16.00 in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on shares of Curis in a research note on Saturday, March 29th. They issued a “hold” rating on the stock.

Curis Trading Up 1.4 %

Shares of CRIS stock opened at $1.48 on Monday. Curis has a 12 month low of $1.40 and a 12 month high of $17.49. The company has a market capitalization of $12.53 million, a P/E ratio of -0.19 and a beta of 3.49. The stock has a 50 day moving average of $2.94 and a two-hundred day moving average of $3.82.

Curis (NASDAQ:CRIS) last issued its earnings results on Monday, March 31st. The biotechnology company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.11. The firm had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. Sell-side analysts predict that Curis will post -7.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Focused Wealth Management Inc grew its holdings in shares of Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 5,138 shares during the last quarter. CM Management LLC grew its stake in Curis by 83.3% during the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after buying an additional 17,820 shares in the last quarter. M28 Capital Management LP raised its stake in shares of Curis by 23.5% in the fourth quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 99,108 shares during the last quarter. Finally, Samsara BioCapital LLC acquired a new position in Curis in the fourth quarter worth $607,000. 29.97% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.